Better prognosis for early blast clearance in leukemia

October 24, 2012
Better prognosis for early blast clearance in leukemia
Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear later, according to a study published in the Nov. 1 issue of Cancer.

(HealthDay)—Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear later, according to a study published in the Nov. 1 issue of Cancer.

Martha Arellano, M.D., from Emory University in Atlanta, and colleagues investigated the association between time to peripheral blood blast clearance after and disease status in 162 patients with .

The researchers found that, 14 days after induction chemotherapy, marrow blast clearance was observed in 84 percent of 119 patients with early peripheral clearance (six days or less) and 60 percent of 43 patients with delayed peripheral clearance (greater than six days). After a median follow-up of 1,538 days, the early clearance group had significantly longer relapse-free survival (442 versus 202 days) and overall survival (930 versus 429 days). After controlling for multiple variables, early peripheral blast clearance was a significant predictor of marrow blast clearance at day 14, , and relapse-free and overall survival.

"Early clearance of peripheral blood blasts after induction chemotherapy predicts for early marrow blast clearance, complete remission, relapse-free survival, and overall survival," Arellano and colleagues conclude. "Early blood blast clearance provides reassuring information to patients early into the course of their therapy and prior to the availability of cytogenetic and , given the association with better relapse-free survival and overall survival."

Explore further: No survival advantage with peripheral blood stem cells versus bone marrow

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Recommended for you

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.